Baseline characteristics

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma · Source last updated 2017-01-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      53

   units

   Participants

groups

1. description

   Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance). Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+. Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.

   id

   BG000

   title

   Carfilzomib, Lenalidomide w/Dexamethasone

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            35

            upper Limit

            81

            value

            59

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            14

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            39

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Gender

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice